Attached files
| file | filename |
|---|---|
| EX-10.62 - EXHIBIT 10.62 - Vyant Bio, Inc. | exh1062njamendlease.htm |
| 10-K - 10-K - Vyant Bio, Inc. | cgix-20171231x10xk.htm |
| EX-31.1 - EXHIBIT 31.1 - Vyant Bio, Inc. | a201710-kex311.htm |
| EX-23.1 - EXHIBIT 23.1 - Vyant Bio, Inc. | a201710-kex231.htm |
| EX-21.1 - EXHIBIT 21.1 - Vyant Bio, Inc. | a201710-kex211.htm |
| EX-10.61 - EXHIBIT 10.61 - Vyant Bio, Inc. | exh1061caamendlease.htm |
| EX-10.60 - EXHIBIT 10.60 - Vyant Bio, Inc. | exh1060sharmarelease.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the annual report of Cancer Genetics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John A. Roberts, Interim Chief Executive Officer, Chief Operating Officer and Executive Vice President, Finance of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: April 2, 2018
/s/ John A. Roberts |
John A. Roberts |
Interim Chief Executive Officer, Chief Operating Officer and Executive Vice President, Finance (Principal Executive Officer and Principal Financial Officer) |
The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.